Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

DMAC DiaMedica Therapeutics Inc

Price (delayed)

$4.2

Market cap

$180.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$177.64M

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases.

Highlights
DMAC's debt is down by 17% year-on-year and by 7% since the previous quarter
The quick ratio has plunged by 56% YoY and by 4.3% from the previous quarter
The net income has contracted by 39% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of DMAC
Market
Shares outstanding
42.88M
Market cap
$180.11M
Enterprise value
$177.64M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.3
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$28.64M
Net income
-$26.97M
EBIT
-$26.94M
EBITDA
-$26.83M
Free cash flow
-$22.6M
Per share
EPS
-$0.64
EPS diluted
-$0.64
Free cash flow per share
-$0.53
Book value per share
$0.79
Revenue per share
$0
TBVPS
$0.91
Balance sheet
Total assets
$38.83M
Total liabilities
$4.88M
Debt
$316,000
Equity
$33.95M
Working capital
$32.76M
Liquidity
Debt to equity
0.01
Current ratio
8.02
Quick ratio
7.88
Net debt/EBITDA
0.09
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-55.5%
Return on equity
-61.3%
Return on invested capital
-69.8%
Return on capital employed
-78.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DMAC stock price

How has the DiaMedica Therapeutics stock price performed over time
Intraday
1.94%
1 week
0.96%
1 month
-0.71%
1 year
48.94%
YTD
-22.65%
QTD
10.82%

Financial performance

How have DiaMedica Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.64M
Net income
-$26.97M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 39% YoY and by 10% from the previous quarter
The operating income has contracted by 37% YoY and by 7% from the previous quarter

Price vs fundamentals

How does DMAC's price correlate with its fundamentals

Growth

What is DiaMedica Therapeutics's growth rate over time

Valuation

What is DiaMedica Therapeutics stock price valuation
P/E
N/A
P/B
5.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 14% YoY and by 7% QoQ
The stock's price to book (P/B) is 61% more than its 5-year quarterly average of 3.3 and 29% more than its last 4 quarters average of 4.1
DiaMedica Therapeutics's equity has decreased by 27% YoY and by 17% from the previous quarter

Efficiency

How efficient is DiaMedica Therapeutics business performance
DiaMedica Therapeutics's return on invested capital has shrunk by 82% YoY and by 20% QoQ
DiaMedica Therapeutics's return on equity has shrunk by 68% YoY and by 18% QoQ
The return on assets has dropped by 60% year-on-year and by 16% since the previous quarter

Dividends

What is DMAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DMAC.

Financial health

How did DiaMedica Therapeutics financials performed over time
DiaMedica Therapeutics's total liabilities has soared by 68% YoY but it has decreased by 13% from the previous quarter
The current ratio has shrunk by 56% YoY and by 3.1% QoQ
DMAC's debt is 99% smaller than its equity
DiaMedica Therapeutics's equity has decreased by 27% YoY and by 17% from the previous quarter
DMAC's debt is down by 17% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.